News coverage about NeoGenomics (NASDAQ:NEO) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NeoGenomics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 46.4473731638662 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
Several equities analysts have recently commented on NEO shares. BidaskClub raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday, February 23rd. ValuEngine lowered NeoGenomics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Scotiabank upped their price target on NeoGenomics from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Tuesday, March 13th. Finally, Royal Bank of Canada upped their price target on NeoGenomics from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Tuesday, March 13th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $16.50.
Shares of NeoGenomics stock opened at $11.34 on Tuesday. NeoGenomics has a 52 week low of $7.08 and a 52 week high of $11.63. The firm has a market capitalization of $906.14 million, a PE ratio of 189.00, a price-to-earnings-growth ratio of 6.24 and a beta of 0.41. The company has a current ratio of 2.03, a quick ratio of 1.85 and a debt-to-equity ratio of 0.53.
NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, May 1st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.01. NeoGenomics had a positive return on equity of 3.19% and a negative net margin of 0.86%. The firm had revenue of $63.40 million for the quarter, compared to analyst estimates of $62.31 million. During the same quarter in the prior year, the company earned $0.03 EPS. NeoGenomics’s revenue was up 10.5% on a year-over-year basis. equities analysts forecast that NeoGenomics will post 0.09 earnings per share for the current fiscal year.
In related news, VP Jennifer Balliet sold 13,000 shares of the stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $11.24, for a total transaction of $146,120.00. Following the transaction, the vice president now owns 13,000 shares of the company’s stock, valued at approximately $146,120. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Steven A. Ross sold 81,999 shares of the stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $10.78, for a total value of $883,949.22. Following the transaction, the insider now directly owns 4,500 shares in the company, valued at approximately $48,510. The disclosure for this sale can be found here. 12.20% of the stock is currently owned by corporate insiders.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.